May 23, 2022
Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation
May 13, 2022
Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix[®] (imlifidase) in kidney transplantation
Apr 21, 2022
Regulatory press releaseHansa Biopharma interim report January – March 2022